Nam augue velit, fermentum sed erat non, efficitur interdum lectus. Donec hendrerit lorem a dui euismod tempus. Vivamus auctor blandit tellus et interdum.
Novel Diagnostic Achieves Medicare Coverage with MCIT Pathway
Client / Setting: Emerging Biopharmaceutical Company | Oncology Biosimilar
The Challenge
First biosimilar launch in competitive oncology market dominated by reference product, physician reluctance, limited commercial infrastructure, and biosimilar education gap.
The Solutions
Integrated commercialization strategy with physician education, payer contracting, pharmacy benefit design, field force deployment, outcomes research, and pull‑through analytics.
Key Results
15% market share achieved in first year (vs 10% target)
$120M first‑year revenue
80% physician trial rate with 65% conversion to regular use
